Drug-induced parkinsonism. Clinical aspects compared with Parkinson disease;Parkinsonismo inducido por farmacos. Aspectos clinicos comparativos con la enfermedad de Parkinson

Revista de Neurologia

Volumn 27, Issue 155, 1998, Pages 35-39

  Errea Abad, J M ^a,d   Ara Callizo, J R ^a,b   Aibar Remon C ^a,c  

^a Hospital Comarcal de Barbastro   (Spain)

^b HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^c UNIVERSITY OF ZARAGOZA   (Spain)

^d HOSPITAL DE BARBASTRO   (Spain)

Author keywords

Calcium antagonists; Drug induced Parkinsonism; Parkinson disease

Indexed keywords

CALCIUM ANTAGONIST; CHLORPROMAZINE; CINNARIZINE; FLUNARIZINE; FLUPENTIXOL; HALOPERIDOL; METHYLDOPA; NEUROLEPTIC AGENT; SULPIRIDE; CALCIUM CHANNEL BLOCKING AGENT;

AGED; ARTICLE; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG INDUCED DISEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PARKINSONISM; CHEMICALLY INDUCED DISORDER; MIDDLE AGED; RETROSPECTIVE STUDY;

AGED; CALCIUM CHANNEL BLOCKERS; CINNARIZINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY; RETROSPECTIVE STUDIES;

EID: 0032109558     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.27155.98056     Document Type: Article

References (22)

1. Martí-Massó JF, Carrera N, Sáez de Buruaga A. Parkinsonismo y temblores inducidos por fármacos. En Martí-Massó JF, Anciones B, eds. Alteraciones neurológicas inducidas por fármacos. Madrid: Ergon; 1993. p. 87-100.
2. Martí-Massó JF, Poza JJ, López de Munain A. Drugs inducing or aggravating parkinsonism: a review. Therapie 1996; 51: 568-77.
3. Martí-Massó JF, Poza JJ. Parkinsonismo inducido o agravado por fármacos: características clínicas y evolución histórica de los fármacos implicados. Neurología 1996; 11: 10-5.
4. Marsden CD, Jenner P. The pathophysiology of extrapyramidal side effects of neuroleptic drugs. Psychol Med 1980; 10: 55-72.
5. Llau ME, Nguyen L, Senard JM, et al. Syndromes parkinsoniens d'origine médicamenteuse: expérience d'un centre régional de pharmacovigilance sur dix ans. Rev Neurol (Paris) 1994; 150: 757-62.
6. Baquero M, Domínguez FJ, Burguera JA, Cruz GA, Muñoz R. Parkinsonismos de novo en ámbito extrahospitalario. Rev Neurol 1995; 23: 964-8.
7. D.G.A. Censo de población de Aragón 1991. Grupos de edad. Provincia de Teruel. Departamento de Economía y Hacienda. Octubre 1994.
8. Hughes AJ, Daniel SE, Kilford L, et al. The accuracy of the clinical diagnosis of Parkinson's disease: a clinico-pathologic study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-4.
9. Crum RM, Anthony JC, Basset SS, Folstein MF. Population-based norms for the Mini-Mental State Examination by age and educational level. JAMA 1993; 269: 2386-91.
10. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1983; 17: 37-49.
11. Morgante L, Rocca WA, Di Rosa AE, et al. Prevalence of Parkin-son's disease and other types of Parkinsonism. Neurology 1992; 42: 1901-7.
12. Menniti-Ippolito F, Spila-Alegiani S, Vanacore N, et al. Estimate of parkinsonism prevalence through drug prescription histories in the province of Rome, Italy. Acta Neurol Scand 1995; 92: 49-54.
13. Sutcliffe RLG, Meara JR. Parkinson's disease epidemiology in the Northampton District, England, 1992. Acta Neurol Scand 1995; 92: 443-50.
14. Trenkwalder C, Schwarz J, Gebhard J, et al. Starnberg trial on epidemiology of parkinsonism and hypertension in the elderly. Arch Neurol 1995; 52: 1017-22.
15. Morgante L, Di Rosa AE, Savettieri G, et al. Drug-induced parkinsonism: prevalence, clinical features and follow-up study in three Sicilian communities. J Neurol 1996; 243: 293-301.
16. Martí-Masssó JF, Carrera N, de la Fuente E. Posible parkinsonismo por cinaricina. Med Clin (Barc) 1985; 85: 614-6.
17. Wilson JA, Primrose WR, Smith RG. Prognosis of drug induced Parkinson's disease. Lancet 1987; I: 443-4.
18. Jiménez FJ, Ayuso Peralta L, Cabrera-Valdivia F, et al. Parkinsonismo farmacológico: casuística en el área sanitaria de Alcalá de Henares. Neurología 1993; 8: 132-3.
19. Stephen PJ, Williamson J. Drug-induced parkinsonism in the elderly. Lancet 1984; II: 1082-3.
20. Gershanik OS. Drug-induced movement disorders. Curr Opin Neurol Neurosurg 1993; 6: 369-76.
21. Giménez-Roldán S, Mateo D. Cinnarizine-induced parkinsonism. Susceptibility related to aging and essential tremor. Clin Neuropharmacol 1991; 14: 156-64.
22. Miller LG, Jankovic J. Metoclopramide-induced movement disorders. Arch Intern Med 1989; 149: 2386-92.